Literature DB >> 10613726

Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites.

M Pérez-Paramo1, J Muñoz, A Albillos, I Freile, F Portero, M Santos, J Ortiz-Berrocal.   

Abstract

Bacterial translocation appears to be an important mechanism in the pathogenesis of spontaneous infections in cirrhosis. Cirrhotic patients are commonly treated with beta-adrenoceptor blockers, but the impact of this treatment in the factors promoting bacterial translocation has not been investigated. This study was aimed at investigating in cirrhotic rats with ascites the effect of propranolol on intestinal bacterial load, transit, and permeability of the bowel and on the rate of bacterial translocation. Bacterial translocation to mesenteric lymph nodes and intestinal bacterial overgrowth, permeability (urinary excretion of (99m)Tc-diethylenetriaminepentaacetic acid [(99m)Tc-DTPA]), and transit (geometric center ratio of (51)Cr) were assessed in 29 rats with carbon tetrachloride (CCl(4)) cirrhosis and 20 controls. These variables were then measured in 12 placebo- and in 13 propranolol-treated ascitic cirrhotic rats. Bacterial translocation was present in 48% of the cirrhotic rats and in none of the controls. Cirrhotic rats with intestinal bacterial overgrowth had a significantly higher rate of translocation and slower intestinal transit than those without it. Among the 15 rats with overgrowth and a (99m)Tc-DTPA excretion greater than 10%, 15 had translocation and 2 had bacterial peritonitis. Only 1 of the 14 rats with either intestinal overgrowth or a (99m)Tc-DTPA excretion greater than 10% presented translocation. Compared with the placebo group, propranolol-treated animals had significantly lower portal pressure, faster intestinal transit, and lower rates of bacterial overgrowth and translocation. In ascitic cirrhotic rats, bacterial translocation results from intestinal overgrowth and severe damage to gut permeability. In this setting, intestinal overgrowth is associated with intestinal hypomotility. Propranolol accelerates the intestinal transit, decreasing the rates of bacterial overgrowth and translocation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10613726     DOI: 10.1002/hep.510310109

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  65 in total

1.  Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

Authors:  Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos
Journal:  World J Hepatol       Date:  2015-08-18

Review 2.  Infection, coagulation, and variceal bleeding in cirrhosis.

Authors:  U Thalheimer; C K Triantos; D N Samonakis; D Patch; A K Burroughs
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

Review 3.  Gut flora and bacterial translocation in chronic liver disease.

Authors:  John Almeida; Sumedha Galhenage; Jennifer Yu; Jelica Kurtovic; Stephen M Riordan
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

Review 4.  Current management of the complications of portal hypertension: variceal bleeding and ascites.

Authors:  Nina Dib; Frédéric Oberti; Paul Calès
Journal:  CMAJ       Date:  2006-05-09       Impact factor: 8.262

5.  Gut microbiota, tight junction protein expression, intestinal resistance, bacterial translocation and mortality following cholestasis depend on the genetic background of the host.

Authors:  Samuel M Alaish; Alexis D Smith; Jennifer Timmons; Jose Greenspon; Daniel Eyvazzadeh; Ebony Murphy; Terez Shea-Donahue; Shana Cirimotich; Emmanuel Mongodin; Aiping Zhao; Alessio Fasano; James P Nataro; Alan Cross
Journal:  Gut Microbes       Date:  2013-04-15

Review 6.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

Review 7.  Markers of bacterial translocation in end-stage liver disease.

Authors:  Ioannis Koutsounas; Garyfallia Kaltsa; Spyros I Siakavellas; Giorgos Bamias
Journal:  World J Hepatol       Date:  2015-09-18

Review 8.  Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.

Authors:  Valerio Giannelli; Vincenza Di Gregorio; Valerio Iebba; Michela Giusto; Serena Schippa; Manuela Merli; Ulrich Thalheimer
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

9.  Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial.

Authors:  Manoj Kumar; Sumit Kainth; Ashok Choudhury; Rakhi Maiwall; Lalita G Mitra; Vandana Saluja; Prashant Mohan Agarwal; Saggere Muralikrishna Shasthry; Ankur Jindal; Ankit Bhardwaj; Guresh Kumar; Shiv K Sarin
Journal:  Hepatol Int       Date:  2019-09-20       Impact factor: 6.047

10.  Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.

Authors:  Yun-Xia Chen; Li-Na Lai; Hui-Ying Zhang; Yang-Hui Bi; Li Meng; Xu-Jiong Li; Xiao-Xia Tian; Li-Min Wang; Yi-Min Fan; Zhong-Fu Zhao; De-Wu Han; Cheng Ji
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.